PMID- 18801052
OWN - NLM
STAT- MEDLINE
DCOM- 20100415
LR  - 20211203
IS  - 1748-1716 (Electronic)
IS  - 1748-1708 (Linking)
VI  - 195
IP  - 4
DP  - 2009 Apr
TI  - Androgen replacement therapy improves function in male rat muscles independently 
      of hypertrophy and activation of the Akt/mTOR pathway.
PG  - 471-82
LID - 10.1111/j.1748-1716.2008.01902.x [doi]
AB  - AIM: We analysed the effect of physiological doses of androgens following 
      orchidectomy on skeletal muscle and bone of male rats, as well as the 
      relationships between muscle performance, hypertrophy and the Akt/mammalian 
      target of rapamycin (mTOR) signalling pathway involved in the control of anabolic 
      and catabolic muscle metabolism. METHODS: We studied the soleus muscle and tibia 
      from intact rats (SHAM), orchidectomized rats treated for 3 months with vehicle 
      (ORX), nandrolone decanoate (NAN) or dihydrotestosterone (DHT). RESULTS: 
      Orchidectomy had very little effect on the soleus muscle. However, maximal force 
      production by soleus muscle (+69%) and fatigue resistance (+35%) in NAN rats were 
      both increased when compared with ORX rats. In contrast, DHT treatment did not 
      improve muscle function. The relative number of muscle fibres expressing slow 
      myosin heavy chain and citrate synthase activity were not different in NAN and 
      ORX rats. Moreover, NAN and DHT treatments did not modify muscle weights and 
      cross-sectional area of muscle fibres. Furthermore, phosphorylation levels of 
      downstream targets of the Akt/mTOR signalling pathway, Akt, ribosomal protein S6 
      and eukaryotic initiation factor 4E-binding protein 1 were similar in muscles of 
      NAN, DHT and ORX rats. In addition, trabecular tibia from NAN and DHT rats 
      displayed higher bone mineral density and bone volume when compared with ORX 
      rats. Only in NAN rats was this associated with increased bone resistance to 
      fracture. CONCLUSION: Physiological doses of androgens are beneficial to muscle 
      performance in orchidectomized rats without relationship to muscle and fibre 
      hypertrophy and activation of the Akt/mTOR signalling pathway. Taken together our 
      data clearly indicate that the activity of androgens on muscle and bone could 
      participate in the global improvement of musculoskeletal status in the context of 
      androgen deprivation induced by ageing.
FAU - Hourde, C
AU  - Hourde C
AD  - INSERM, Paris, France.
FAU - Jagerschmidt, C
AU  - Jagerschmidt C
FAU - Clement-Lacroix, P
AU  - Clement-Lacroix P
FAU - Vignaud, A
AU  - Vignaud A
FAU - Ammann, P
AU  - Ammann P
FAU - Butler-Browne, G S
AU  - Butler-Browne GS
FAU - Ferry, A
AU  - Ferry A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081013
PL  - England
TA  - Acta Physiol (Oxf)
JT  - Acta physiologica (Oxford, England)
JID - 101262545
RN  - 0 (Anabolic Agents)
RN  - 0 (Androgens)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 6PG9VR430D (Nandrolone)
RN  - EC 2.3.3.1 (Citrate (si)-Synthase)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.6.4.1 (Myosin Heavy Chains)
RN  - H45187T098 (Nandrolone Decanoate)
SB  - IM
MH  - Anabolic Agents/therapeutic use
MH  - Androgens/*therapeutic use
MH  - Animals
MH  - Bone Density/drug effects
MH  - Citrate (si)-Synthase/metabolism
MH  - Dihydrotestosterone/therapeutic use
MH  - *Hormone Replacement Therapy
MH  - Hypertrophy
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Male
MH  - Muscle, Skeletal/*drug effects/*pathology/physiopathology
MH  - Muscular Diseases/*drug therapy/*physiopathology
MH  - Myosin Heavy Chains/metabolism
MH  - Nandrolone/analogs & derivatives/therapeutic use
MH  - Nandrolone Decanoate
MH  - Oncogene Protein v-akt/*metabolism
MH  - Orchiectomy
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Rats
MH  - TOR Serine-Threonine Kinases
MH  - Tibia/drug effects/metabolism/pathology
EDAT- 2008/09/20 09:00
MHDA- 2010/04/16 06:00
CRDT- 2008/09/20 09:00
PHST- 2008/09/20 09:00 [pubmed]
PHST- 2010/04/16 06:00 [medline]
PHST- 2008/09/20 09:00 [entrez]
AID - APS1902 [pii]
AID - 10.1111/j.1748-1716.2008.01902.x [doi]
PST - ppublish
SO  - Acta Physiol (Oxf). 2009 Apr;195(4):471-82. doi: 
      10.1111/j.1748-1716.2008.01902.x. Epub 2008 Oct 13.